None listed
Conditions
Interventions
Drug : Subjects who meet the exclusion criteria for selection of test results are randomly assigned to the tegoprazan 50mg group or the
esomeprazole 40mg group at the same ratio of 1:1, and take 2 t
Sponsors
Koera University Guro Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Those whose age is 20 to 75 years old as of the date of obtaining written consent 2) Patients diagnosed with gastric adenoma or early gastric cancer and underwent endoscopic submucosal dissection (ESD) for treatment purposes 3) In any of the following cases -Gastric adenoma -Undifferentiated early gastric cancer of less than 2.0 cm, limited to the mucous membrane and without ulcers -Differentiated early gastric cancer limited to the mucous membrane regardless of the size of the lesion and without ulcers -Differentiated early gastric cancer of less than 3.0 cm limited to the mucous membrane and accompanied by ulcers -Differentiated early gastric cancer less than 3.0 cm invading the submucosal layer less than 500 µm and not accompanied by ulcers 4) When the maximum diameter of the specimen of the removed iatrogenic ulcer is less than 4 cm 5) Those who understand and follow instructions and can participate in the entire clinical trial period 6) A person who voluntarily decides to participate and agrees in writing to the consent of the subject 7) Those who agreed to use contraceptive methods (including medically impossibility of pregnancy) during the clinical trial period
Exclusion criteria
Exclusion criteria: 1) If overt bleeding or perforation occurs within 48 hours after endoscopic submucosal dissection (ESD) (hematmesis, bloody stool, black stool symptoms, suspected perforation on radiography, etc.) 2) In case of esophageal stenosis, ulcer stenosis, pyloric stenosis, peptic ulcer and perforation on upper gastrointestinal endoscopy 3) If there is a history of previous upper gastrointestinal surgical resection 4) Those who are unable to perform follow-up upper gastrointestinal endoscopy 5) Those who have a history of hypersensitivity reactions to components of tegoprazan or proton pump inhibitors or benzimidazoles 6) Those who are administering atazanavir, nelpinavir, or drug containing rilpivirine, terfenadine, cisapride, pimozide, astemizole 7) pregnant or lactating women 8) Uncontrolled cardiopulmonary disease, kidney disease, liver disease, endocrine disease (especially in patients with severe diabetes), cranial nerve disease, etc. 9) When it is difficult to conduct appropriate research due to cognitive or intellectual disability 10) If you are taking antipsychotics, antidepressants, or anti-anxiety drugs 11) When taking PPI, H2 blocker, or prokinetics within 2 weeks before endoscopic submucosal dissection (ESD) 12) If you need to continue taking steroids, NSAIDs, aspirin and other antiplatelet drugs, anticoagulants, etc. during the clinical trial period 13) When AST, ALT, ALP, GGT, total bilirubin levels are more than twice the upper limit reference value (or BUN, creatinine levels are more than 1.5 times the upper limit reference value)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Healing rate by endoscopy of the upper gastrointestinal tract | — |
Secondary
| Measure | Time frame |
|---|---|
| 8 weeks cumulative healing rate | — |
Countries
Korea, Republic of
Contacts
Public Contactwon shik kim
Koera University Guro Hospital
Outcome results
None listed